Investigational Drug Information for Telcagepant
✉ Email this page to a colleague
What is the drug development status for Telcagepant?
Telcagepant is an investigational drug.
There have been 11 clinical trials for Telcagepant.
The most recent clinical trial was a Phase 3 trial, which was initiated on August 14th 2008.
The most common disease conditions in clinical trials are Migraine Disorders, Heart Diseases, and Coronary Artery Disease. The leading clinical trial sponsors are Merck Sharp & Dohme Corp. and [disabled in preview].
Summary for Telcagepant
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 80 |
| WIPO Patent Applications | 54 |
| Japanese Patent Applications | 19 |
| Clinical Trial Progress | Phase 3 (2008-08-14) |
| Vendors | 52 |
Recent Clinical Trials for Telcagepant
| Title | Sponsor | Phase |
|---|---|---|
| Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065) | Merck Sharp & Dohme Corp. | Phase 2/Phase 3 |
| Positron Emission Tomography (PET) Study of Brain Calcitonin Gene-Related Peptide (CGRP) Receptor Occupancy After Telcagepant Administration (MK-0974-067) | Merck Sharp & Dohme Corp. | Phase 1 |
| A Study to Test the Safety and Effectiveness of MK-0974 (Telcagepant) Co-administered With Ibuprofen or Acetaminophen in Patients With Migraines With or Without Aura (MK-0974-046) | Merck Sharp & Dohme Corp. | Phase 2 |
Clinical Trial Summary for Telcagepant
Top disease conditions for Telcagepant
Top clinical trial sponsors for Telcagepant
US Patents for Telcagepant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
